Article Sidebar
Views PDF: 191
Adherence to antiplatelet therapy in patients after 6 months of percutaneous coronary intervention and some factors affecting
Main Article Content
Abstract
Objectives: To investigate the status of adherence to antiplatelet therapy in patients after 6 months of Percutaneous Coronary Intervention (PCI) by the Morisky Medication Adherence Scale – MMAS.[1]
Methods & Results: From June 2022 to February 2023, we prospectively enrolled 250 patients after percutaneous coronary intervention, aged 67.7 ± 10 years (73.2% male) had measured by MMAS. The Score of adherence to antiplatelet therapy in patients was 5,9 ± 1,2 points. The patients with non Adherence and moderate adherence accounted for the majority of 50,4% and 38,8%. Patients with a high degree of adhrence to drug therapy accounted for a low rate of 10,8%. Characteristics of education level and understanding of coronary artery disease that affect adherence to antiplatelet therapy in patients after 6 months intervention with p<0.001. Gender characteristics, demographics, comorbidities and chest pain status did not affect the patient's adherence to treatment.
Conclusion: Patients who did not adhere to heantiplatelet therapy after 6 months of intervention accounted for 50.4%. Factors affecting the patient's adherence to antiplatelet therapy after 6 months of percutaneous coronary intervention include education level, understanding of the disease, and drug side effects.
Article Details
Keywords
Morisky Medication adhrence Scale, Percutaneous Coronary Intervention, Cardiovascular diseases
References
2. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. 2007;30(4):616-622. doi:10.1183/09031936.00021707 %J European Respiratory Journal
3. Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. 2015;95(1-2):50-58.
4. Czarny MJ, Nathan AS, Yeh RW, Mauri L. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clinical cardiology. Aug 2014;37(8):505-13. doi:10.1002/clc.22289
5. Luu NM, Dinh AT, Nguyen TTH, Nguyen VHJBri. Adherence to antiplatelet therapy after coronary intervention among patients with myocardial infarction attending Vietnam National Heart Institute. 2019;2019
6. Latry P, Martin-Latry K, Lafitte M, Peter C, Couffinhal TJE. Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database. 2012;7(12):1413-1419.
7. Morisky DE, Ang A, Krousel‐Wood M, Ward HJJTjoch. Predictive validity of a medication adherence measure in an outpatient setting. 2008;10(5):348-354.
8. Moon SJ, Lee W-Y, Hwang JS, Hong YP, Morisky DEJPo. Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. 2017;12(11):e0187139.
9. Morisky DE, Green LW, Levine DMJMc. Concurrent and predictive validity of a self-reported measure of medication adherence. 1986:67-74.
10. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. Journal of clinical hypertension (Greenwich, Conn). May 2008;10(5):348-54. doi:10.1111/j.1751-7176.2008.07572.x
11. Nguyễn Thiên Vũ TVH, Nguyễn Thắng Các bộ câu hỏi đánh giá tuân thủ điều trị ở bệnh nhân tim mạch Tạp chí Tim mạch học Việt Nam 2021;93
12. Fennessy MM, Devon HA, Ryan C, Lopez JJ, Zerwic JJ. Changing illness perceptions and adherence to dual antiplatelet therapy in patients with stable coronary disease. The Journal of cardiovascular nursing. Nov-Dec 2013;28(6):573-83. doi:10.1097/JCN.0b013e31825d6060
13. Kähkönen O, Kankkunen P, Saaranen T, Miettinen H, Kyngäs HJNO. Hypothetical model of perceived adherence to treatment among patients with coronary heart disease after a percutaneous coronary intervention. 2020;7(1):246-255.